Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nolvadex Falls To Generic Competition: AstraZeneca To Discontinue Tamoxifen

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca will pull its breast cancer therapy Nolvadex at the end of June.

You may also be interested in...



Lilly Gets Its Wish: STAR Results Show Evista Reduces Breast Cancer Risk

Trial shows Lilly’s Evista reduces risk of developing invasive breast cancer by 50%, comparable to AstraZeneca’s Nolvadex.

GAO Urges Congress To Place EPO, Other Dialysis Services In Bundled Rates

The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel